


Empowering investors to make informed decisions

DOWNLOAD YOUR COMPLIMENTARY COPY



PSYCH

Psych.global


Sign up for free updates from Psychedelic Health

Sign up for free

RESEARCH

# Neurobehavioral study evaluates efficacy and safety of Amanita extract

The study evaluated Psyched Wellness' AME-1 extract.



Published 2 years ago on 29th March 2023

By **Stephanie Price**



Photo by [Micael Widell](#) on [Unsplash](#)



**Psyched Wellness has carried out a neurobehavioral study evaluating the safety and efficacy of its Amanita Muscaria extract – AME-1.**

The result of the study shows that AME-1 alone or in combination with ethanol did not impair any learning or memory state, motor coordination, balance or altered

- Rec
- Landmark UK trial for opioid addicts
- European Citizen psychedelic therapy
- Psilocybin versus depression shows
- Shortwave Life Science shows positive results
- UK's first trade agreement for psychedelics launched
- Millions could be helped by psychedelic therapy, shows new study

- DMT for major depressive disorder shows promising results
- Ceruvia to launch psychedelic therapy trial



behavioural activity.

The neurobehavioral study was to evaluate the efficacy and safety of Amanita muscaria extract (AME-1) alone, and in combination with ethanol, in a behavioural test battery including the Morris water maze (MWM), accelerating rotarod (RR) test, balance beam (BB) and forced swim tests (FST).

**See also** [Psyched Wellness: Amanita muscaria for the masses](#)

All of these tests are designed to look at behavioural despair, memory and learning, motor coordination, and maintaining balance.

Brian Tancowny, a scientific advisor for Psyched Wellness commented: “This milestone event further provides information in the toxicological assessment of AME-1.

“The results of this study further increases the knowledge in a scientific setting indicating no negative behavioural and neurological functional changes with the use of AME-1.”

**See also** [Amanita extract could boost antiviral immune response in the brain](#)

The importance of this study in conjunction with the other toxicity studies is to provide scientific evidence for the efficacy and safety of AME-1. This study further understands the effects of AME-1 under a scientific methodology that reinforces a safe dose for human consumption.

KGK, a licensed CRO in Canada, completed the study.

Previous Psyched Wellness research has demonstrated that the extract holds a potential new functional property – inhibiting human mast cell activation – which could potentially work as a treatment for inflammatory skin conditions.

Additionally, *in vivo* findings have demonstrated that AME-1 has a potential priming effect on the immune system, allowing it to more efficiently respond to pathogens.

**RELATED TOPICS:** [#AMANITA MUSCARIA](#) [#FEATURED](#) [#PSYCHEDELICS RESEARCH](#)

←

DON'T MISS

**Mind Medicine Australia funds studies investigating psilocybin and MDMA**

UP NEXT


**Systematic ayahuasca review shows changes to acute brain connectivity**

→


#### You may like



**Psyched Wellness: Amanita muscaria for the masses**



**Phase 1 study with 5-MeO-DMT formulation successfully completed**



**Psilocybin trial receives FDA approval for IND application**


New report on drinking ayahuasca

Australian psilocybin trial

Lion's mane I include it in



**Psychedelics can lessen fear of death and dying, shows study**



**Over 5.5 million US adults use hallucinogens**



**Amanita extract could boost antiviral immune response in the brain**

[CLICK TO COMMENT](#)

## RESEARCH

# Landmark UK trial to investigate psilocybin for opioid addiction relapse



Published 8 months ago on 30th October 2024

By **Stephanie Price** [Twitter](#)



**For the first time, a government-funded UK trial will investigate psilocybin-assisted psychotherapy for targetting relapses associated with opioid addiction, aiming to bring an innovative new therapy to the NHS if successful.**

Research shows that the UK had the world's highest rate of opioid consumption in 2019, amounting to a serious public health concern. Further, [figures](#) show that around 140,000 people are accessing treatment for opioid dependence in the country. Despite the prevalence of opioid addiction, there are currently limited medicines to help prevent relapses during recovery.

CONTINUE READING

## RESEARCH

# Psilocybin versus escitalopram for depression shows positive results



Published 9 months ago on 2nd October 2024  
By **Stephanie Price** [Twitter](#)



## A six-month follow-up study of a Phase 2 clinical trial investigating psilocybin versus escitalopram for the treatment of major depressive disorder has shown positive results.

Around 30% of people living with depression in the UK are [resistant](#) to current treatments, highlighting an urgent need for new therapies. As the researchers of this study highlight, even for patients who have had their depression successfully treated, there is a high risk of relapse, with one in three patients relapsing within the year.

Equally, SSRI treatments often include side effects such as sexual dysfunction, weight gain, fatigue, and emotional blunting.

CONTINUE READING



---

RESEARCH

# Shortwave Life Sciences psilocybin drug shows positive results in anorexia trial



Published 10 months ago on 19th September 2024

By **Stephanie Price** [Twitter](#)




**Shortwave Life Sciences has announced it has achieved a significant breakthrough in its ambitions to transform eating disorder care with positive pre-clinical results from its latest pharmacodynamics study, demonstrating the safety of its psilocybin-based drug combination for the treatment of anorexia nervosa.**

Anorexia nervosa has one of the highest fatality rates. The condition is a complex mental health condition as well as a metabolic disease, yet no FDA-approved pharmacological treatments are currently available for the condition.

[CONTINUE READING](#)

---

Trending




MEDICINAL / 3 years ago  
**MDMA: the love drug?**



INSIGHT / 2 years ago  
**2C-B: If LSD and MDMA had a baby**



INSIGHT / 4 years ago  
**Mixing psychedelics with lithium poses significant risk of seizures**



INSIGHT / 2 years ago  
**Why does hangover,**



INSIGHT / 2 years ago  
**Ketamine: understanding the K-Hole**



OPINION / 3 years ago  
**Clerkenwell Health is launching a free UK psychedelic therapist training programme**



MEDICINAL / 2 years ago  
**What we know about the effect of psychedelics on women's health**



INTERVIEWS / 2 years ago  
**Psyched W muscaria'**

 **PsychCapital**Health



[PRIVACY POLICY](#) [COOKIE POLICY](#) [TERMS AND CONDITIONS](#)

PsychCapital Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. We do not promote the personal use of psychedelic compounds. Please seek professional medical advice if you are concerned about any of

Copyright © 2023 Psych Capital Plc